These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 15496640)

  • 21. Absence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique.
    Browne TR; Szabo GK; Leppik IE; Josephs E; Paz J; Baltes E; Jensen CM
    J Clin Pharmacol; 2000 Jun; 40(6):590-5. PubMed ID: 10868309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
    Kim DW; Yoo MW; Park KS
    Epilepsy Behav; 2012 Apr; 23(4):497-9. PubMed ID: 22440324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital.
    Hasegawa H
    Curr Med Res Opin; 2004 May; 20(5):577-80. PubMed ID: 15140322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zonisamide in epilepsy: a pilot study.
    Wilensky AJ; Friel PN; Ojemann LM; Dodrill CB; McCormick KB; Levy RH
    Epilepsia; 1985; 26(3):212-20. PubMed ID: 4006880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
    Kothare SV; Valencia I; Khurana DS; Hardison H; Melvin JJ; Legido A
    Epileptic Disord; 2004 Dec; 6(4):267-70. PubMed ID: 15634623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zonisamide: a new antiepileptic drug.
    Sobieszek G; Borowicz KK; Kimber-Trojnar Z; Małek R; Piskorska B; Czuczwar SJ
    Pol J Pharmacol; 2003; 55(5):683-9. PubMed ID: 14704463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interaction of zonisamide in rats. Effect of zonisamide on other antiepileptics.
    Kimura M; Tanaka N; Kimura Y; Miyake K; Kitaura T; Fukuchi H
    Biol Pharm Bull; 1993 Jul; 16(7):722-5. PubMed ID: 8401412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults.
    Chien S; Bialer M; Solanki B; Verhaeghe T; Doose DR; Novak G; Yao C
    Epilepsia; 2006 Nov; 47(11):1830-40. PubMed ID: 17116022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients.
    Park SP; Hwang YH; Lee HW; Suh CK; Kwon SH; Lee BI
    Epilepsy Behav; 2008 Jan; 12(1):102-8. PubMed ID: 17945539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zonisamide in the management of epilepsy--Japanese experience.
    Ohtahara S
    Epilepsy Res; 2006 Feb; 68 Suppl 2():S25-33. PubMed ID: 16321507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of 'Mentat' on the pharmacokinetics of single and multiple doses o phenytoin in rabbits.
    Garg SK; Islam AS; Kumar N; Sehgal M; Bhargava VK
    Neurol India; 1999 Jun; 47(2):104-7. PubMed ID: 10402333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zonisamide in the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2010 Jan; 11(1):115-26. PubMed ID: 20001433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Introduction to zonisamide.
    Baulac M
    Epilepsy Res; 2006 Feb; 68 Suppl 2():S3-9. PubMed ID: 16413170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zonisamide: physician and patient experiences.
    Marmarou A; Pellock JM
    Epilepsy Res; 2005; 64(1-2):63-9. PubMed ID: 15869867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy.
    Barel S; Yagen B; Schurig V; Soback S; Pisani F; Perucca E; Bialer M
    Clin Pharmacol Ther; 1997 Apr; 61(4):442-9. PubMed ID: 9129561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients.
    Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M
    Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical prescribing and long-term efficacy and safety of zonisamide.
    Leppik IE
    Epilepsy Res; 2006 Feb; 68 Suppl 2():S17-24. PubMed ID: 16406743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.